The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study

BACKGROUND: PD-1/L1 inhibitor-based immunotherapy is currently under investigation in biliary tract cancer (BTC). Apatinib combined with camrelizumab has achieved promising results in various tumor types. The aim of this study was to assess the safety and efficacy of apatinib plus camrelizumab for a...

全面介紹

Na minha lista:
書目詳細資料
發表在:Front Oncol
Main Authors: Wang, Dongxu, Yang, Xu, Long, Junyu, Lin, Jianzhen, Mao, Jinzhu, Xie, Fucun, Wang, Yunchao, Wang, Yanyu, Xun, Ziyu, Bai, Yi, Yang, Xiaobo, Guan, Mei, Pan, Jie, Seery, Samuel, Sang, Xinting, Zhao, Haitao
格式: Artigo
語言:Inglês
出版: Frontiers Media S.A. 2021
主題:
Oncology
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8071846/
https://ncbi.nlm.nih.gov/pubmed/33912461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.646979
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍